Advertisement
Home Day 4

Day 4

Isatuximab, Pomalidomide, and Dexamethasone Combo Improves Health-Related Quality of Life in Difficult-to-Treat Populations

Among patients with relapsed/refractory multiple myeloma (MM), treatment with isatuximab plus pomalidomide and dexamethasone (IsaPd), compared with pomalidomide and dexamethasone alone (Pd),...

Can Ixazomib Improve Survival for Newly Diagnosed Patients with Multiple Myeloma?

The international, multicenter, double-blind, placebo-controlled, phase III TOURMALINE-MM4 trial found that post-induction maintenance ixazomib in non–transplant-eligible newly diagnosed patients with multiple myeloma...

Factors Impacting Mortality in Chronic Lymphocytic Leukemia

A study presented at the 2020 ASH Annual Meeting found that most patients with chronic lymphocytic leukemia (CLL) die from causes unrelated...

Study Compares Effectiveness of Pegcetacoplan Versus Ravulizumab for PNH

Researchers compared the effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) and found that pegcetacolplan resulted in improvements...
Advertisement
Advertisement